Insider Selling: Forty Seven Inc (FTSV) Director Sells 10,000 Shares of Stock

Forty Seven Inc (NASDAQ:FTSV) Director Irving Weissman sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $15.98, for a total transaction of $159,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Irving Weissman also recently made the following trade(s):

  • On Friday, April 5th, Irving Weissman sold 9,900 shares of Forty Seven stock. The shares were sold at an average price of $17.11, for a total transaction of $169,389.00.
  • On Friday, March 29th, Irving Weissman sold 100 shares of Forty Seven stock. The shares were sold at an average price of $18.00, for a total transaction of $1,800.00.
  • On Wednesday, February 27th, Irving Weissman sold 26,384 shares of Forty Seven stock. The shares were sold at an average price of $16.98, for a total transaction of $448,000.32.
  • On Monday, February 4th, Irving Weissman sold 9,664 shares of Forty Seven stock. The stock was sold at an average price of $15.02, for a total transaction of $145,153.28.
  • On Monday, January 28th, Irving Weissman sold 336 shares of Forty Seven stock. The stock was sold at an average price of $15.00, for a total transaction of $5,040.00.
  • On Wednesday, January 9th, Irving Weissman sold 10,000 shares of Forty Seven stock. The stock was sold at an average price of $17.05, for a total transaction of $170,500.00.

NASDAQ:FTSV traded down $0.92 during trading hours on Friday, hitting $17.88. 200,912 shares of the company were exchanged, compared to its average volume of 174,236. The company has a market cap of $559.14 million and a PE ratio of -4.77. Forty Seven Inc has a 52-week low of $12.02 and a 52-week high of $23.83.

Forty Seven (NASDAQ:FTSV) last released its earnings results on Thursday, March 28th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.10. As a group, research analysts anticipate that Forty Seven Inc will post -2.61 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in FTSV. Bourgeon Capital Management LLC purchased a new stake in Forty Seven during the fourth quarter worth $6,827,000. BlackRock Inc. boosted its holdings in Forty Seven by 1,203.9% during the third quarter. BlackRock Inc. now owns 446,363 shares of the company’s stock worth $6,659,000 after buying an additional 412,129 shares in the last quarter. Citadel Advisors LLC boosted its holdings in Forty Seven by 144.4% during the third quarter. Citadel Advisors LLC now owns 572,923 shares of the company’s stock worth $8,548,000 after buying an additional 338,489 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Forty Seven by 51.2% during the third quarter. JPMorgan Chase & Co. now owns 346,066 shares of the company’s stock worth $5,164,000 after buying an additional 117,142 shares in the last quarter. Finally, Vanguard Group Inc boosted its holdings in Forty Seven by 144.4% during the third quarter. Vanguard Group Inc now owns 171,060 shares of the company’s stock worth $2,553,000 after buying an additional 101,060 shares in the last quarter. 43.53% of the stock is currently owned by hedge funds and other institutional investors.

FTSV has been the subject of several recent analyst reports. Oppenheimer set a $35.00 price objective on shares of Forty Seven and gave the stock a “buy” rating in a research note on Friday, January 11th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Forty Seven in a research report on Monday, January 14th. Zacks Investment Research downgraded shares of Forty Seven from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. FIG Partners started coverage on shares of Forty Seven in a research report on Friday, February 1st. They set a “buy” rating and a $30.00 target price on the stock. Finally, Guggenheim started coverage on shares of Forty Seven in a research report on Friday, April 12th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Forty Seven presently has an average rating of “Buy” and a consensus target price of $26.50.

TRADEMARK VIOLATION WARNING: This piece was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/irving-weissman-sells-10000-shares-of-forty-seven-inc-ftsv-stock.html.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

Read More: How Investors Use a Balance Sheet

Insider Buying and Selling by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.